Human induced pluripotent stem cell (iPSC)-based models are a valuable resource for studying disease mechanisms in vitro at the cellular level, screening potential new therapeutics, and investigating the propensity and mechanism for the development of toxic side effects caused by a drug treatment. Such iPSC-based models enable research to be performed under defined experimental conditions and in a reproducible manner. [Read more…]
Mesoblast (ASX:MSB; Nasdaq: MESO) announced that the U.S. FDA granted the company’s product candidate, Revascor, Orphan Drug Designation for prevention of gastrointestinal bleeding in patients with left ventricular assist devices.
Revascor, Mesenchymal Precursor Cells
Revascor is Mesoblast’s investigational cell therapy composed of 150 million allogeneic mesenchymal precursor cells (MPCs). [Read more…]
I had the honor of interviewing Dr. Ruby Yanru Chen-Tsai, Chief Scientific Officer and Co-founder of Applied StemCell Inc. (ASC), a fast growing biotechnology company in Milpitas, California. Specializing in gene-editing technologies and stem cell innovation, ASC offers an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications.
In this fascinating interview, we discuss Dr. Yanru Chen-Tsai’s impressive background, ASC’s unique product portfolio, its TARGATT™ gene editing technology, and the company’s future trajectory. [Read more…]
Lung diseases can be debilitating, making both medical leaders and patients interested in exploring stem cell treatments for lungs. Find out what you need to know about stem cell therapy for lungs, including risks, benefits, clinical trial progress and more.
A Look At Stem Cell Treatments For Lungs
In this article:
- Progression of Treatments for Lung Diseases
- Where Do Stem Cells for Lungs Come From?
- How Do Scientists and Physicians Harvest and Use These Cells?
- Risks of Stem Cell Treatments for Lungs
- Benefits of Stem Cell Treatments for Lungs
- Lung Stem Cell Clinical Trials
Hamburg, Germany, June 5, 2019 — Evotec SE announced that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $9.0 m to Evotec.
Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Since then, the companies have achieved several milestones including advancement of one programme into lead optimisation as well as including additional cell lines and now a new cell type. [Read more…]